AzTrials
AzTrials

Acute Kidney InjuryNCT06889116

VExUS Score and AKI in Critically Ill Adult patients-a Prospective Observational Study.

An observational study of Acute Kidney Injury and VExUS, run by Tribhuvan University Teaching Hospital, Institute Of Medicine. at 1 site in Nepal.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Introduction Renal perfusion is dependent on the renal perfusion pressure across the renal capillaries. Venous congestion due to excess fluid therapy can drastically reduce the renal perfusion pressure in spite of a normal mean arterial pressure. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Acute Kidney Injury, VExUS
How many people
52 participants
Where
1 siteNepal
Study dates
15 May 2023to 11 Jan 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients who had AKI at the time of admission or who developed AKI during their ICU stay were screened for inclusion.

Who may be able to join

  • Age ≥18 years
  • Admitted to the adult ICUs of TUTH (ICU A and ICU B)
  • Admitting diagnosis of AKI or who developed AKI during their ICU stay

Who cannot join

  • Pregnancy
  • Diagnosed case of chronic kidney disease
  • Diagnosed case of cirrhosis/ portal hypertension
  • Arrhythmias which would interfere with the acquisition and interpretation of the Doppler waveforms
  • Inferior venacava thrombus
  • Poor window for assessment

Trial locations and contacts

1 site in 1 country.

Nepal1 site
  • Tribhuvan University Teaching Hospital

    Mahārājgañj, Bagmati, 44600

Other trials in Nepal

About this study

Official title: Correlation of Point of Care Venous Excess Ultrasonography (VExUS) Score and Acute Kidney Injury (AKI) in Critically Ill Adult Patients- a Prospective Observational Study.

Introduction Renal perfusion is dependent on the renal perfusion pressure across the renal capillaries. Venous congestion due to excess fluid therapy can drastically reduce the renal perfusion pressure in spite of a normal mean arterial pressure. Increasing cumulative fluid balance during the ICU stay has been found to be associated with negative outcomes including acute kidney injury (AKI) and hospital mortality. Venous excess ultrasound (VExUS) to assess the Doppler studies of renal, hepatic and portal veins along with the inferior venacava has been shown to reliably predict the incidence of AKI in certain ICU patient population more specifically in cardiorenal syndrome. The aim of this study was to correlate the incidence of AKI and VExUS scores in a mixed ICU population and hence determine the contribution of venous congestion on the causation of AKI in a general ICU.

Methods:

The patients included who have AKI at admission or developed AKI during their ICU stay were included. The definition of AKI used for this study was as defined by Kidney Disease: Improving Global Outcomes (KDIGO). Point of care VExUS scans were done on each patient at inclusion (day 0), then each day for a total of 4 days (day 1, 2 and 3), till initiation of renal replacement therapy, death or discharge form the ICU. Correlation between VExUS grades and creatinine clearances was explored as the primary objective.

Keywords
VExUS, Acute Kidney Injury, Cumulative fluid balance, Point of Care Ultrasound
Medical subject headings
Acute Kidney Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06889116
Study groupRoleWhat they receive
Patients with AKIPatients who are admitted with the diagnosis of AKI or develop AKI during their ICU stay

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To determine correlation between the VExUS score with creatinine clearance.

    Measured: At the end of Day 3 or initiation of renal replacement therapy or resolution of AKI, death or discharge from the ICU. whichever came first.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Mar 2025
  2. Study start15 May 2023
  3. Primary completion7 Jan 2024
  4. Study completion11 Jan 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
52 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06889116
Sponsor's protocol ID
438(6-11)E2- 079/080
Status last verified
Mar 2025
First submitted
15 Mar 2025
Last updated
21 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Kidney Injury and VExUS, run by Tribhuvan University Teaching Hospital, Institute Of Medicine. at 1 site in Nepal.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Nepal. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To determine correlation between the VExUS score with creatinine clearance. (time frame: At the end of Day 3 or initiation of renal replacement therapy or resolution of AKI, death or discharge from the ICU. whichever came first.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in